Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter

Date: 03/29/2022

Product Type: Drugs, Potential Foreign Material

Company Announcement Date:  March 29, 2022

FDA Publish Date: March 29, 2022

Product Type: Drugs

Reason for Announcement:  Potential Particulate Matter (silica and iron oxide)

Company Name:  Teva Pharmaceuticals

Brand Name:  Teva Pharmaceuticals

Product Description:  IDArubicin Hydrochloride Injection USP